Navigation Links
Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
Date:9/30/2010

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms.

Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related quality of life questionnaire (HRQL) for Parkinson's disease comprising eight items – mobility, activities of daily living, emotional well-being, social support, cognition, communication, bodily discomfort and stigma.

"Data from the RECOVER trial demonstrated improvements in motor and non-motor symptoms for people living with Parkinson's disease as well as worthwhile changes in the quality of their everyday lives, including their daily activities, their emotional well being and their cognitive and communication abilities," said Herve Lilliu, Head of Health Outcomes and Access, UCB.

The RECOVER trial was a multicenter, multinational, double-blind, placebo-controlled study designed to assess the effects of rotigotine in controlling early morning motor function and non-motor symptoms that affect the everyday lives of people with early- and late-stage Parkinson's disease. Patients were randomized (2:1) to receive rotigotine (2-16 mg/24 h) or placebo during a titration period lasting up to 8 weeks, followed by a 4-week maintenance period.

PDQ-8 data were obtained from measurements taken at baseline and at the end of the 12 week study from 89 placebo- and 176 rotigotine-randomized patients. Mean change from baseline PDQ-8 total score was greater in the rotigotine group (-6.9 [SD: 11.9]) than the placebo group (-1.2 [SD: 13.7]; p<0.001). Both the rotigotine effect size (-0.41) and standardized response mean (-0.58) were moderate based on the Cohen definition of change (0.20 sm
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
2. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
5. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
6. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, ... Global Biotechnology, Inc. for the compounding, packaging and distributing of ... in the United States . ... capable of compounding naltrexone tablets in various strengths for individual ...
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... Feb. 1 Obese teenagers who,succeeded in losing weight ... their bone mineral content increase over that,period, say researchers ... because adolescence is a critical period for bone,health in ... of the journal Obesity studied 62,adolescents between the ages ...
... as part of innovative,Therapeutics Development Initiative, NEW YORK, ... do whatever it takes to speed delivery of transformative,treatments ... Fox,Foundation for Parkinson,s Research has awarded up to $3 ... push potential new PD treatments,closer to the clinic. The ...
Cached Medicine Technology:Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 2Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently delivers ... to have it lead the wedding dress industry into the ... dresses for the global market. , “The CEO of VogueQueen ... focuses on continuing the goal of operational excellence and giving ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... used for prevention of pregnancy for decades and more recently ... that wearing a condom during intercourse may not give good ... and syphilis. ,There has been a rise recently in ... the news may come as a surprise to many. Current ...
... risk of having a pre-term baby may perhaps will like ... that pomegranate juice can prevent brain injury the fetus may ... in case of a pre-term delivery., ,Pomegranate juice contains ... property of neuroprotection and anti-aging effects. ,Researchers from ...
... People may be reacting to varying degrees of energy loss ... // genetic predisposition. How our bodies react to exercise programs ... to exercising like the level of blood glucose in the ... works of scientists from Washington University School of Medicine, exercise ...
... Cancer Society researchers conducted in interesting national survey that ... look at the prevailing myths about cancer in the minds ... 957 adults with no history of cancer to assess their ... identify any associated misconceptions. Participants were asked if five misconceptions ...
... in temperate countries or colder regions of the world would ... Vitamin D in the winter months when the sunlight exposure ... formation of the active component of Vitamin D in the ... bones for later years. The researchers concluded in a study ...
... low birth weight may be at heightened risk// of cardiovascular ... as for the fathers. ,In a research done by ... that leads to low birth weight stems may lead to ... genetic condition coming from the parents. Hence parents of the ...
Cached Medicine News:Health News:Condoms May not be safe Enough 2Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
Hemisphere modular Cup....
Medicine Products: